Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
75 76 Next >
News headline image
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
From AstraZeneca
Via Business Wire
News headline image
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say ↗
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market. 
Via Benzinga
News headline image
Why Is AstraZeneca Stock Sinking On Tuesday? ↗
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock falls around 7% 
Via Benzinga
News headline image
Smart Money Is Betting Big In AZN Options ↗
 
Via Benzinga
News headline image
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
Via Talk Markets
News headline image
AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug ↗
AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety, tolerability, and convenient dosing. 
Via Benzinga
News headline image
3 Magnificent Stocks Under $100 to Buy in November ↗
The price could be right for these stocks. 
Via The Motley Fool
News headline image
3 Rock-Solid Dividend Stocks You Can Buy and Hold Forever ↗
In a frothy market starved for value, these three dividend stocks combine reasonable valuations with the proven ability to disrupt themselves. 
Via The Motley Fool
News headline image
Monopar Therapeutics Skyrockets 400% on Licensing Deal
Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug. 
Via MarketBeat
News headline image
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast ↗
Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat estimates, reaching €13.44 billion, up 12.3%. 
Via Benzinga
News headline image
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder ↗
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder. 
Via Benzinga
News headline image
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
News headline image
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
News headline image
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain ↗
GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future growth persist as challenges with its drug pipeline remain. 
Via Benzinga
Topics Lawsuit
News headline image
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
News headline image
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks ↗
Investing in the most popular players in the space isn't the only valid approach. 
Via The Motley Fool
News headline image
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge ↗
 
Via Benzinga
Topics Stocks
News headline image
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher ↗
 
Via Benzinga
News headline image
US Stocks Open Lower; Dow Tumbles Over 150 Points ↗
 
Via Benzinga
Topics Stocks
News headline image
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline ↗
AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp(a) disruptor aimed at treating cardiovascular disease. Airsupra, AstraZeneca's asthma drug, shows promise in a... 
Via Benzinga
News headline image
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses ↗
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization... 
Via Benzinga
News headline image
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
News headline image
AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review ↗
AstraZeneca's Calquence receives FDA Priority Review for previously untreated mantle cell lymphoma, showing promising Phase 3 trial results in reducing disease progression by 27%. An FDA decision is... 
Via Benzinga
News headline image
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
From AstraZeneca
Via Business Wire
News headline image
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next ↗
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
Via Benzinga
Topics Economy
News headline image
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit 
Via News Direct
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
From AstraZeneca
Via Business Wire
News headline image
Is Summit Therapeutics Stock a Buy? ↗
Its alliance with a successful foreign biotech could be decisive for the stock. 
Via The Motley Fool
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.